872360-18-4

Basic information

• Product Name: 6-Oxa-2-azabicyclo[3.2.0]heptane-3,7-dione, 4-(2-chloroethyl)-1-[(R)-(1S)-2-cyclohexen-1-ylhydroxymethyl]-5-methyl-, (1R,4R,5S)-
• CAS NO: 872360-18-4
• Molecular Formula: C15H20ClNO4
• Molecular Weight: 313.781
• Mol File: 872360-18-4.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 6-Oxa-2-azabicyclo[3.2.0]heptane-3,7-dione, 4-(2-chloroethyl)-1-[(R)-(1S)-2-cyclohexen-1-ylhydroxymethyl]-5-methyl-, (1R,4R,5S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Oxa-2-azabicyclo[3.2.0]heptane-3,7-dione, 4-(2-chloroethyl)-1-[(R)-(1S)-2-cyclohexen-1-ylhydroxymethyl]-5-methyl-, (1R,4R,5S)-(872360-18-4)
• EPA Substance Registry System: 6-Oxa-2-azabicyclo[3.2.0]heptane-3,7-dione, 4-(2-chloroethyl)-1-[(R)-(1S)-2-cyclohexen-1-ylhydroxymethyl]-5-methyl-, (1R,4R,5S)-(872360-18-4)

Safety Data

• Hazardous Substances Data: 872360-18-4(Hazardous Substances Data)

Upstream product

• 943542-56-1 C₁₅H₂₁NO₅ 
• 872360-17-3 NPI-2062 
• 952512-39-9 C₂₇H₃₇NO₅ 
• 952512-37-7 C₂₁H₂₉NO₅ 
• 952512-38-8 C₂₁H₂₇NO₅ 
• 943542-61-8 C₂₂H₂₉NO₆ 
• 943542-55-0 C₂₂H₂₇NO₇ 
• 943542-54-9 C₂₅H₃₇SiNO₆ 
• 943542-53-8 C₂₂H₂₉NO₆ 
• 943542-52-7 C₂₇H₃₇NO₆ 
• 943542-64-1 C₂₀H₃₃NO₅ 
• 943542-45-8 C₂₇H₃₇NO₅ 
• 943542-46-9 C₂₁H₂₇NO₅ 
• 943542-62-9 C₂₁H₂₉NO₅ 

Downstream Products

• 872360-17-3 NPI-2062 
• 437742-34-2 salinosporamide A 

Relevant articles and documents

A METHOD OF USING PROTEASOME INHIBITORS IN COMBINATION WITH HISTONE DEACETYLASE INHIBITORS TO TREAT CANCER

Disclosed are methods of treating cancer comprising administering to the animal, a therapeutically effective amount of proteasome inhibitors and one or more histone deacetylase inhibitor. The animal is a mammal, preferably a human or a rodent.

Enantioselective total synthesis of (-)-salinosporamide A (NPI-0052)

A novel enantioselective total synthesis of 20S proteasome inhibitor Salinosporamide A (NPI-0052; 1) is presented. Key features include intramolecular aldol cyclization of 6 to simultaneously generate the three chiral centers of advanced intermediate 5, cyclohexene ring addition using B-2-cyclohexen-1-yl-9-BBN, and inversion of the C-5 stereocenter by oxidation followed by enantioselective enzymatic reduction.

METHODS OF USING [3.2.0] HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF FOR THE TREATMENT OF LUNG CANCER

Disclosed are methods of treating lung cancer comprising administering to the animal, a therapeutically effective amount of a heterocyclic compound, alone or in combination with another therapeutic.